163 related articles for article (PubMed ID: 36809324)
1. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
Lebwohl MG; Hebert AA; Gooderham MJ
JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
[No Abstract] [Full Text] [Related]
2. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
Smith B; Collier MR; Wu JJ
JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
[No Abstract] [Full Text] [Related]
3. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
4. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
6. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Snape SD; Wigger-Alberti W; Goehring UM
Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
8. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
[TBL] [Abstract][Full Text] [Related]
9. Severe multi-refractory Sneddon-Wilkinson disease, with fast response to oral roflumilast treatment.
Peñuelas Leal R; Grau Echevarría A; Labrandero Hoyos C; Blaya Imbernon D; Lorca Sprohnle J; Finello M; Mayo Martinez F; Zaragoza Ninet V
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e467-e469. PubMed ID: 38059421
[No Abstract] [Full Text] [Related]
10. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
12. [Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].
Shmelev EI; Shmeleva NM
Ter Arkh; 2012; 84(6):73-6. PubMed ID: 22997924
[TBL] [Abstract][Full Text] [Related]
13. An update on topical therapies for psoriasis.
Pender EK; Kirby B
Curr Opin Rheumatol; 2024 Jul; 36(4):289-294. PubMed ID: 38651512
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast for Chronic Plaque Psoriasis.
Cordoro KM
JAMA; 2022 Sep; 328(11):1049-1050. PubMed ID: 36125485
[No Abstract] [Full Text] [Related]
15. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
17. [Clinical profile of roflumilast].
Izquierdo Alonso JL
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: A potential drug for the treatment of cognitive impairment?
Sugin LJS; Murugesan A; Bindu M; Sunil KN
Neurosci Lett; 2020 Sep; 736():135281. PubMed ID: 32735939
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED
Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
